Helicobacter pylori Infections is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Helicobacter pylori Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Helicobacter pylori Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Helicobacter pylori Infections overview
Helicobacter pylori (H. pylori) infection occurs when the Helicobacter pylori (H. pylori) bacteria infect the stomach, typically during childhood. A leading cause of stomach ulcers, this infection is asymptomatic for many, with over half of the global population potentially affected. Recognition often arises when peptic ulcer symptoms manifest, prompting healthcare providers to test for H. pylori. Peptic ulcers, affecting the stomach (gastric ulcer) or the initial part of the small intestine (duodenal ulcer), are indicative of H. pylori involvement. Antibiotics form the primary treatment for H. pylori infection, emphasizing the importance of diagnosis and intervention in managing peptic ulcer complications.
For a complete picture of PTSR and LoA scores for drugs in Helicobacter pylori Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
